Introduction {#s1}
============

The Thai-Myanmar border harbors some of the world\'s most drug resistant malaria parasites. *Plasmodium falciparum* parasites in this region have developed significant resistance to commonly used antimalarials, except the artemisinin derivatives. The treatment of uncomplicated *P. falciparum* malaria in Thailand has been modified several times during the past 30 years to counter the rapid emergence and spread of drug resistance [@pone.0004551-Chareonviriyaphap1], [@pone.0004551-Rooney1]. A two-day combination of mefloquine and artesunate, MAS~2~, (artesunate 6 mg/kg repeated once 24 hours later), was introduced in Thailand in 1995, under strict supervision, exclusively in three provinces (including the northwestern border of Thailand) where failure rates with mefloquine (15 mg/kg) -sulfadoxine-pyrimethamine (MSP) had risen above 50% [@pone.0004551-Wongsrichanalai1]. In 2004, MAS~2~ was extended to all provinces along the borders with Myanmar and Cambodia, following evidence from these areas of inadequate clinical cure rates with mefloquine alone, or MSP [@pone.0004551-Rojanawatsirivej1]--[@pone.0004551-Vijaykadga1]. Use of both drugs has been strictly controlled and neither mefloquine nor artesunate are available in the private sector on the Thai side of the border.

In camps for displaced persons located along the Thai-Myanmar border, mefloquine and artesunate combination therapy has been evaluated since 1991 and deployed systematically since 1994 [@pone.0004551-Nosten1], [@pone.0004551-Luxemburger1]. The total dose of artesunate (12 mg/kg) was the same as that in the National protocol, but the duration of the treatment was 3 days (4 mg/kg/day) i.e. MAS~3~, to ensure that artesunate covered two parasite asexual life-cycles, thereby reducing the parasite biomass exposed to mefloquine alone [@pone.0004551-White1]. MAS~3~, one of the ACT regimens currently recommended by the WHO, is also used in clinics serving the migrant population, located along the Thai-Myanmar border, and since January 2008 has replaced MAS~2~ in the Thailand National protocol.

This report presents a continuous description of the in vivo, in vitro and molecular correlates of MAS~3~ efficacy in the thirteen years between January 1995 and December 2007 in camps for displaced people and clinics for migrant workers located along the northwestern border of Thailand.

Methods {#s2}
=======

Study area {#s2a}
----------

The epidemiology of malaria in the area has been described in detail elsewhere [@pone.0004551-Luxemburger2]. Briefly, malaria is seasonal, the transmission is low and unstable, *P. falciparum* and *P. vivax* are the two predominant species, *P. malariae* is occasionally found, and *P. ovale* is rare. All age groups are affected and nearly all the *P. falciparum* infections are symptomatic. Since 1995, the Shoklo Malaria Research Unit (SMRU) has conducted 7 prospective randomized open-label controlled chemotherapeutic trials of new antimalarial drugs in which MAS~3~ was one of the treatment arms [@pone.0004551-vanVugt1]--[@pone.0004551-Ashley3] and two non-comparative trials of MAS~3~ drug efficacy [@pone.0004551-Price1].

Assessment of treatment regimens {#s2b}
--------------------------------

Three methodologies were use to evaluate MAS~3~ efficacy: in vivo, in vitro and molecular assessment of *pfmdr1* copy number. The in vivo efficacy of MAS~3~ has been monitored annually [@pone.0004551-Price1], [@pone.0004551-Nosten2]. The prospective analysis of in vivo efficacy was restricted to studies after 1994, when distinction of recrudescent from novel infections was made possible by the introduction of PCR parasite genotyping [@pone.0004551-Brockman1], thereby ensuring accurate assessment of recrudescence rates. Post-treatment follow-up was extended to 42--63 days to minimize underestimation of true failure rates [@pone.0004551-White2], [@pone.0004551-Stepniewska1].

In vitro antimalarial drug susceptibility studies were carried out on fresh isolates of *P. falciparum* parasites from 1995 onwards [@pone.0004551-Brockman2]. Studies in this location have demonstrated that amplification of *pfmdr1* gene copy number is the major molecular determinant of mefloquine susceptibility and provides an important tool for monitoring drug resistance [@pone.0004551-Anderson1], [@pone.0004551-Price2].

In vivo studies of drug efficacy {#s2c}
--------------------------------

### Study procedures {#s2c1}

Specific study procedures have been described previously for each randomized controlled trial [@pone.0004551-vanVugt1]--[@pone.0004551-Ashley3]; most enrolment procedures were common to all studies. In brief patients, who presented to the SMRU clinics (all located along 100 km of the Thai-Myanmar border) with a microscopically confirmed uncomplicated *P. falciparum* malaria or a mixed infection, were enrolled after giving written (all randomized trials and all non-comparative trials since 1996) or witnessed verbal consent (non-comparative trials conducted in 1995). Severely ill patients and hyperparasitaemic patients (4% or more infected red blood cells on a thin malaria smear) were treated with different regimens and were not included in this analysis. Patients who had received treatment with mefloquine in the previous 63 days or who had failed their last antimalarial drug treatment, pregnant women, children \<5 kg in body weight, and patients with signs of severity or concomitant disease were excluded from the studies. All patients were examined daily until fever subsided (fever being defined as an axillary, rectal or tympanic temperature≥37.5°C) and until parasite clearance (defined as the absence of *P. falciparum* trophozoites on the malaria smear), and then followed weekly for 6 to 9 weeks. In the event of parasite reappearance during follow up patients were re-treated and followed-up again. The clinical trials conducted at SMRU were all reviewed by the Ethics Committee of the Faculty of Tropical Medicine Mahidol University and the Oxford Tropical Research Ethics Committee.

### Drug regimens {#s2c2}

Patients received oral artesunate (Guilin Pharmaceutical Factory, Guilin, Guangxi, People\'s Republic of China) or Arsumax® (Sanofi-Aventis, Gentilly-France) 4 mg/kg/day for 3 days once daily, and mefloquine 25 mg base/kg, Lariam® (Roche, Basel-Switzerland) or Mequin® (Atlantic Laboratories, Bangkok-Thailand). Children who were unable to swallow complete tablets received the same weight-adjusted dosage of crushed tablets mixed with water. Each drug administration was observed in all patients.

Patients received mefloquine either as a single dose of 25 mg/kg (during trials conducted before 1996), as a split dose of 15 mg/kg and 10 mg/kg given 24 hrs apart on the second and third day of treatment (the current protocol), or as a split dose of 8 mg/kg given once a day for 3 days in two trials [@pone.0004551-Ashley1], [@pone.0004551-Ashley2].

In the 2006 dose-assessment study [@pone.0004551-Ashley3], half of the patients received a newly developed fixed co-formulation of mefloquine HCl 220 mg (or mef 200)+artesunate 100 mg (adult tablet) and mefloquine HCl 55 mg (or mef 50)+artesunate 25 mg (paediatric tablet), (Far-Manguinhos, Brazil), given once a day for 3 days according to body weight. This fixed dose combination has been shown to have comparable oral bioavailability and efficacy with the loose combination [@pone.0004551-Ashley3].

### Outcome measures {#s2c3}

Recurrent infection was defined as the presence of asexual forms of *P. falciparum* parasite on a blood smear between day-5 and 45 of follow-up (42 days+3 days to take into account a delay in the last follow-up). Recrudescent infections were differentiated from new infections using 3 loci genotyping as described previously [@pone.0004551-Brockman1]. Patients with recurrent infection were usually treated with 7 days of artesunate (2 mg/kg/day), which was combined with 7 days of doxycycline 4 mg/kg/day (T.O. Chemicals Ltd, Bangkok-Thailand) in patients \>8 years old.

In view of the importance of the parasite reduction ratio [@pone.0004551-White3], delayed parasite clearance was considered if patients were still parasitaemic 48 hours (day-2) after the baseline malaria positive smear.

In vitro studies of P. falciparum drug susceptibility {#s2d}
-----------------------------------------------------

Parasites isolates were obtained from patients with acute *P. falciparum* malaria infection attending the research clinics. Only primary infections were assessed. Isolates were collected if the parasite density was at least 5 parasites/1,000 red blood cells (RBC), from patients attending the clinic, whether enrolled in one of the studies or not. Venous blood (5 ml) was collected into a sterile Vacutainer® tube containing 0.05 ml Potassium-EDTA. Samples were kept at room temperature and transported within the next 4--6 hours to the main laboratory, where they were set up in continuous culture immediately. The minimum parasitaemic threshold required for parasite growth in culture, as well as the necessity to take 5 ml of blood limited the evaluation of *P. falciparum* drug susceptibility to patients with higher parasitaemia who agreed to have a venopuncture (usually adults).

### In vitro drug assay {#s2d1}

Drug susceptibility testing by hypoxanthine uptake has been described previously by Brockman [@pone.0004551-Brockman2]. Briefly sodium artesunate (AS), and mefloquine (MFQ) were dissolved in 70% ethanol at a concentration of 1 mg/ml, and serial dilutions (683 ng/ml to 0.67 ng/ml for mefloquine and 33.46 ng/ml to 0.03 ng/ml for artesunate) were made in complete RPMI medium. The solvent in the final concentrations had no significant effect on parasite growth when compared to culture media. All concentrations, including drug-free controls, were distributed in duplicate in 96-well tissue culture plates. The drug-plates were made in bulk and stored at −80°C until use (for up to 3 months). The reproducibility of IC~50~ measurements was assessed regularly using cloned K1 isolates of *P. falciparum*.

Molecular analysis of pfmdr1 {#s2e}
----------------------------

DNA for molecular analysis of *pfmdr1* copy number was available from whole blood (in EDTA or heparinised tubes, stored at −70°C), or from 50 µl of capillary blood transferred to Whatman™ filter paper. In order to investigate changes in resistance markers over time parasite genotypes were assessed each year since 1996, with the exception of 1998, 2000 and 2007, using venous blood taken before treatment from a random selection of patients with primary *P. falciparum* infections. Randomisation was stratified by age and sex to represent the population seeking care for malaria in the outpatient\'s clinics.

*Pfmdr1* copy number was assessed by quantitative PCR (ABI sequence detector 7700; Applied Biosystems™) using the methods described previously [@pone.0004551-Price2]. All reactions were performed in triplicate and were rejected if they did not conform to exponential kinetics. Single nucleotide polymorphisms in *pfmdr1* were detected by nested PCR-RFLP methods as described [@pone.0004551-Price2]. All PCRs and digests included as positive and negative controls DNA of laboratory strains 3D7, HB3, 7G8 and Dd2, respectively.

Statistical Analysis {#s2f}
--------------------

Data were analyzed using SPSS for Windows™ (Version 14, SPSS Inc.) and STATA (Version 10, Stata Corp.). Differences in settings, sequence randomization, mefloquine treatment timing, and study procedures were included in the assessment of heterogeneity between studies using the Cochran Q test and the I2 test [@pone.0004551-Higgins1]. The cumulative risk of failure at day-42 was calculated by survival using the Kaplan Meier method. Indeterminate genotyping results and new infections were censored at the date of the reappearance of the *P. falciparum* parasites. PCR results were deemed indeterminant if only one of the three gene locus was amplified, or if analysis of genetic frequency of alleles in the population revealed a recrudescent pair as statistically insignificant [@pone.0004551-Brockman1]. The risks of treatment failure (PCR-adjusted) over time were compared by the Mantel-Haenszel log rank test. In the multivariate analysis, temporal trends in efficacy were assessed by using a Cox regression model after controlling for known risk factors such as age, parasitaemia at baseline, and mixed parasite infection. Non-adjusted and adjusted Hazard ratios (HR and AHR) and Odds ratios (OR and AOR) were also presented. A stepwise logistic regression was used to analyze the changes in delayed parasite clearance time, with the model including variables significantly associated to parasite clearance time in the univariate analysis (level of significance if *p*\<0.10), as well as other potential risks factors such as age, sex, admission parasitaemia, mixed parasite infection, and type of drug regimen.

Gametocytaemia was considered as a binary variable (present/absent) and analyzed on admission, at day-1, 2, 3, 7, and weekly thereafter until day-42. Gametocyte carriage rates were presented as person-gametocyte-weeks (PGW, number of weeks patients had gametocytes/number of weeks patients were followed-up), and expressed per 1,000 weeks of follow-up. Prevalence rate on admission, overall carriage rate and among patients without gametocyte on admission were calculated yearly.

In vitro dose-response curves were analyzed by fitting the data to an inhibitory E-max pharmacokinetic model using WINNONLIN (Version 4.1, Pharsight Corporation) and the IC~50~ values, and coefficients of variation calculated. Temporal trends for mefloquine and artesunate IC~50~ were analyzed on the ln-transformed data.

Regression analysis on the ln-transformed values was performed to investigate association between the IC~50~ and the *pfmdr1* copy number using the isolates for which both the IC~50~ and the copy number were available.

Changes in *pfmdr1* copy number, gametocyte carriage rates, and the proportions of patients remaining febrile and/or parasitaemic on day 2--4 over the years were analyzed by χ^2^ test for trend.

Results {#s3}
=======

The efficacy of the MAS~3~ combination was evaluated in 3,264 patients with uncomplicated *P. falciparum* malaria infections, enrolled in 9 trials, between 1995 and 2007 ([**Table 1**](#pone-0004551-t001){ref-type="table"}). Heterogeneity between studies was low and was not significant (I^2^ test = 34%, *p* = 0.109, Cochran Q test).

10.1371/journal.pone.0004551.t001

###### Patients enrolled in antimalarial drug efficacy trials who received MAS~3~, between 1995 and 2007, on the northwestern border of Thailand.

![](pone.0004551.t001){#pone-0004551-t001-1}

                                                                      1995      1996      1997     1998      1999      2000     2001      2002      2003      2004      2005      2006      2007
  -------------------------------------------------- -------------- --------- --------- -------- --------- --------- -------- --------- --------- --------- --------- --------- --------- ---------
  **Randomized Controlled Trials**                                                                                                                                                        
  Van Vugt et al. 1998                                  N = 305        31        274                                                                                                      
  Van Vugt et al. 2000                                   N = 43                            29       14                                                                                    
  Van Vugt et al. 2002                                  N = 534                                     156       280       98                                                                
  Hutagalung et al. 2005                                N = 245                                                                  160       85                                             
  Ashley et al. 2004&05                                 N = 343                                                                            127       210        6                         
  Ashley et al. 2006                                    N = 500                                                                                                187       313              
  Unpublished                                           N = 240                                                                                                          17        134       89
  **Sub-total**                                       **N = 2210**   **31**    **274**   **29**   **170**   **280**   **98**   **160**   **212**   **210**   **193**   **330**   **134**   **89**
  **Open trials for routine monitoring of MAS~3~**                                                                                                                                        
  Price et al. 1997                                     N = 453        451        2                                                                                                       
  Unpublished                                           N = 601                                                                  246                 42        145       70        49        49
  **Sub-total**                                       **N = 1054**   **451**    **2**    **0**     **0**     **0**    **0**    **246**    **0**    **42**    **145**   **70**    **49**    **49**
  **Total**                                           **N = 3264**   **482**   **276**   **29**   **170**   **280**   **98**   **406**   **212**   **252**   **338**   **400**   **183**   **138**

The admission characteristics of patients are presented in [**Table 2**](#pone-0004551-t002){ref-type="table"}. Overall 36% (1,159/3,264) of the patients enrolled were children under 15 years. In adults, there was a preponderance of males (73%, 1,533/2,105). Overall 19% (*n* = 625) of patients did not complete the 42-day follow-up period. The main reasons for loss of follow-up were change of address and employment obligations (592/625). The drug combination was generally well tolerated and few patients reported having serious adverse events [@pone.0004551-vanVugt1]--[@pone.0004551-Price1]. Only one patient (0.03%; 95% CI, 0.0--0.2) deteriorated after starting MAS~3~ and required parenteral treatment; three deaths were reported (0.09%; 95% CI, 0.02--0.31). None were related to malaria or to an adverse drug event. There were no significant differences in age, sex and presence of mixed infections on admission between patients lost to follow up and those who completed it.

10.1371/journal.pone.0004551.t002

###### Demographic characteristics on admission of patients enrolled in antimalarial drug efficacy trials who received MAS~3~, between 1995 and 2007.
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                                             1995          1996          1997         1998          1999          2000         2001          2002          2003          2004          2005          2006          2007          Total
  -------------------------------------- ------------- ------------- ------------ ------------- ------------- ------------ ------------- ------------- ------------- ------------- ------------- ------------- ------------- --------------
  No enrolled                                 482           276           29           170           280           98           406           212           252           338           400           183           138           3264
  No of males (%)                          291 (60%)     190 (69%)     26 (90%)     126 (74%)     183 (65%)     67 (68%)     258 (64%)     142 (67%)     153 (61%)     215 (64%)     283 (71%)     145 (79%)     121 (88%)     2200 (67%)
  Age (years)                                                                                                                                                                                                                
  \<15 years                              317 (65.8%)   92 (33.3%)    6 (20.7%)    50 (29.4%)    88 (31.4%)    38 (38.8%)   158 (38.9%)   80 (37.7%)    95 (37.7%)    107 (31.7%)   115 (28.8%)    9 (4.9%)      4 (2.9%)     1159 (35.5%)
  ≥15 years                               165 (34.2%)   184 (66.7%)   23 (79.3%)   120 (70.6%)   192 (68.6%)   60 (61.2%)   248 (61.1%)   132 (62.3%)   157 (62.3%)   231 (68.3%)   285 (71.2%)   174 (95.1%)   134 (97.1%)   2105 (64.5%)
  No with mixed infections (%)            86 (17.8%)     13 (4.7%)     1 (3.4%)     6 (3.5%)      20 (7.1%)     4 (4.1%)     36 (8.9%)     20 (9.4%)     23 (9.1%)     19 (5.6%)     30 (7.5%)     13 (7.1%)     2 (1.4%)      273 (8.4%)
  Geometric mean parasitaemia (per µl)       6745          4932          7798         5984          3776          3228         7161          10544         10765         8375          7907          9226          7674           6982
  Min                                         16            13           631           20             6            20           13            16            79            50            32            158           158            6
  Max                                       199526        251189        125893       251189        501187        158489       199526        199526        199526        316228        316228        199526        158489         501187

Clinical and parasitological responses {#s3a}
--------------------------------------

Changes in fever clearance times were evaluated in the 2,029 (62%) of patients who presented with fever ([**Table 3**](#pone-0004551-t003){ref-type="table"}). Overall, 91.4% (95% CI, 90.1--92.6) of patients were afebrile by day-2, and 98.7% (95% CI, 98.0--99.1) by day-3 without significant time trend. Mean haematocrit on admission was 37.1% (95% CI, 36.9--37.3) and remained unchanged over the 13 year period. Mean fractional reductions in haematocrit from baseline at day-7 did not differ significantly by year (overall mean reduction of 7.4%; 95% CI, 6.9--7.9).

10.1371/journal.pone.0004551.t003

###### Fever and parasite clearance time (in days).
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                               1995         1996        1997        1998         1999        2000         2001         2002         2003         2004         2005         2006        2007         Total
  ------------------------ ------------ ------------ ----------- ----------- ------------ ----------- ------------ ------------ ------------ ------------ ------------ ------------ ----------- -------------
  **Fever clearance**                                                                                                                                                                           
  Febrile (N, %)                                                                                                                                                                                
  Day 0 (admission)         406 (100)    169 (100)    20 (100)    104 (100)   170 (100)    44 (100)    301 (100)    118 (100)     87 (100)    179 (100)    256 (100)    131 (100)    44 (100)    2029 (100)
  Day 1                     199 (49.0)   68 (40.2)    7 (35.0)    35 (33.7)   65 (38.2)    14 (31.8)   141 (46.8)   29 (24.6)    18 (20.7)    55 (30.7)    90 (35.2)    64 (48.9)    18 (40.9)   803 (39.6)
  Day 2                     43 (10.6)    22 (13.0)    5 (25.0)     4 (3.8)     9 (5.3)      2 (4.5)     25 (8.3)     4 (3.4)      3 (3.4)     19 (10.6)     22 (8.6)     13 (9.9)     3 (6.8)     174 (8.6)
  Day 3                      5 (1.2)      6 (3.6)     2 (10.0)     1 (1.0)     1 (0.6)         0        1 (0.3)         0         1 (1.1)      5 (2.8)      4 (1.6)         0         1 (2.3)     27 (1.3)
  Day 4                      2 (0.5)         0            0           0           0            0           0            0            0         2 (1.1)      1 (0.4)         0            0         5 (0.2)
  Day 5                      1 (0.2)         0            0           0           0            0           0            0            0            0         1 (0.4)         0            0         2 (0.1)
  **Parasite clearance**                                                                                                                                                                        
  Smear positive (N, %)                                                                                                                                                                         
  Day 0 (admission)         468 (100)    273 (100)    29 (100)    168 (100)   279 (100)    98 (100)    402 (100)    211 (100)    252 (100)    337 (100)    393 (100)    182 (100)    126 (100)   3218 (100)
  Day 1                     189 (40.4)   106 (38.8)   20 (69.0)   96 (57.1)   150 (53.8)   53 (54.1)   274 (68.2)   159 (75.4)   201 (79.8)   276 (81.9)   320 (81.4)   122 (67.0)   91 (72.2)   2057 (63.9)
  Day 2                      17 (3.6)     9 (3.3)      2 (6.9)    10 (6.0)     16 (5.7)     5 (5.1)    47 (11.7)    46 (21.8)    42 (16.7)    108 (32.0)   118 (30.0)   31 (17.0)    25 (20.0)   476 (14.8)
  Day 3                         0            0            0        1 (0.6)     1 (0.4)         0        8 (2.0)      8 (3.8)      13 (5.2)     19 (5.6)     26 (6.6)     3 (1.6)      1 (0.8)     80 (2.5)
  Day 4                         0            0            0           0           0            0        2 (0.5)      1 (0.5)      1 (0.4)      7 (2.1)      1 (0.3)      1 (0.6)         0        13 (0.4)
  Day 5                         0            0            0           0           0            0           0            0            0         1 (0.3)      1 (0.3)         0            0         2 (0.1)

Parasite clearance times were available for 3,218 patients (98.6%), ([**Table 3**](#pone-0004551-t003){ref-type="table"}). There was a significant increase in the proportion of patients failing to clear their parasitaemia by day-2 over the study period (*p*\<0.001, test for trend). Before 2001, 95.5% (1,256/1,315) were aparasitaemic within 48 hours compared to 78.1% (1,487/1,903) between 2001 and 2007 (OR = 5.96; 95% CI, 4.49--7.90, *p*\<0.001). By day-3, 99.8% (1,313/1,315) patients had cleared their parasitaemia before 2001, but this fell to 95.9% (1,825/1,903) thereafter, (*p*\<0.001), ([**Figure 1**](#pone-0004551-g001){ref-type="fig"}). Whereas until the end of 2000, no patients (0/1,315) were parasitaemic on day-4, between 2001 and 2007 there were 13 patients (0.7%) with parasites seen on day-4 (*p* = 0.007).

![Percentage of patients who had cleared parasitaemia at Day-2 and Day-3 1995--2007.](pone.0004551.g001){#pone-0004551-g001}

After accounting for age, sex, presence of a mixed (*P. falciparum*+*P. vivax*) infection, and haematocrit on admission, the increase in parasite clearance time over the 13 year study period remained significant (AOR = 1.11; 95% CI, 1.06--1.16, *p*\<0.001) with a 0.05% annual increase of patients with delayed parasitaemia. In the same multivariate analysis, parasitaemia on admission (AOR = 2.47; 95% CI, 2.13--2.87, *p*\<0.001), gametocytaemia on admission (AOR = 1.59; 95% CI, 1.07--2.37, *p* = 0.023), and site of recruitment (AOR = 0.32; 95% CI, 0.23--0.45, *p* = 0.001) were significantly associated with failure to clear parasitaemia within 48 hours.

Gametocyte carriage {#s3b}
-------------------

Overall 6.3% (196/3,109) of patients had patent gametocytaemia on admission and this proportion increased from 1.2% (6/482) in 1995 to 7.2% (10/139) in 2007 (*p* = 0.001, test for trend), resulting in a significant increase in gametocyte carriage rate over the study period (*p* = 0.001, test for trend), ([**Table 4**](#pone-0004551-t004){ref-type="table"}). However, the gametocyte carriage rate among patients without gametocyte on admission remained unchanged throughout the study period (*p* = 0.30, test for trend).

10.1371/journal.pone.0004551.t004

###### Gametocyte prevalence rate on admission and gametocyte carriage rate (overall and among patients without gametocytaemia on admission).
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                                                  1995   1996   1997   1998   1999   2000   2001   2002   2003   2004   2005   2006   2007
  ---------------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  **Gametocytaemia on admission**                                                                                                    
  Total number of patients                        482    276     29    168    279     98    400    212    252    337    400    176    139
  Prevalence (%)                                   1%     6%     7%    11%     8%     7%     3%     6%     5%     9%    10%    11%     7%
  **Overall gametocyte carriage rate**                                                                                               
  Person-weeks of follow-up                       1658   1052   143    641    988    382    2036   1148   1326   1817   2086   919    722
  Gametocyte carriage (in weeks)                   9      10    0.6     19     15     10     14     12     13     33     42     21     11
  Gametocyte carriage rate (per 1000 PGW)          5      10     4      29     15     27     7      10     10     18     20     23     15
  **Patients without gametocyte on admission**                                                                                       
  Person-weeks of follow-up                       1569   939    127    554    888    336    1912   1048   1223   1419   1846   803    650
  Gametocyte carriage (in weeks)                   6      1      0      2      2      1      6      2      3      6      6      6      2
  Gametocyte carriage rate (per 1000 PGW)          4      1      0      4      3      3      3      2      2      5      3      7      3

Patients who cleared their parasitaemia on day-1 had a lower gametocyte carriage (10 per 1,000 person-gametocyte-week (or PGW); 95% CI, 7--13) than those whose parasitaemia was cleared on day-2 (15 per 1,000 PGW; 95% CI, 13--18, *p* = 0.009), or on day-3 or later (20 per 1,000 PGW; 95% CI, 14--26, *p* = 0.051), ([**Figure 2**](#pone-0004551-g002){ref-type="fig"}).

![Relationship between parasite clearance time and gametocyte carriage.\
Gametocyte carriage rate is expressed per 1,000 person-gametocyte-week (PGW).](pone.0004551.g002){#pone-0004551-g002}

The majority of patients without gametocytaemia on admission, who later developed gametocytaemia, did so on day-1 (43%). The proportion of patients with gametocyte appearance during follow-up did not increase significantly over the years (*p* = 0.082, test for trend), but was related to the parasite clearance time; it increased from 2.9% (74/2,580) among patients who cleared their parasitaemia on day-1 or on day-2 to 5.9% (26/437) among those who cleared their parasitaemia on day-3 or later, *p* = 0.001.

In the multivariate analysis, after controlling for gametocytaemia on admission (AOR = 1.65; 95% CI, 1.09--2.49, *p* = 0.018), parasitaemia on admission (AOR = 2.32; 95% CI, 2.00--2.69, *p* = 0.001), year of recruitment (AOR = 1.16; 95% CI, 1.11--1.22, *p* = 0.001), and site of recruitment (AOR = 0.37; 95% CI, 0.26--0.51, *p* = 0.001), patients who had a delayed parasite clearance (3 days or longer) remained at a higher risk of developing gametocytaemia (AOR = 2.29; 95% CI, 2.00--2.69, *p* = 0.002).

Parasitological efficacy {#s3c}
------------------------

Of the 333 recurrent infections with *P. falciparum* during the 42-day follow-up period, 177 (53%) were new infections, 108 (32%) were recrudescent infections, and in 48 (15%) cases the PCR result was inconclusive (*n* = 15) or samples were not available (*n* = 33). The median time to recrudescence occurred at 21 days of follow-up (range 7--42 days); although time to recrudescence has increased by one week since 2006, it has not changed significantly over the 13 year period, and neither has the time to re-infection ([**Table 5**](#pone-0004551-t005){ref-type="table"}).

10.1371/journal.pone.0004551.t005

###### PCR-confirmed novel and recrudescent infections and time to recrudescence.

![](pone.0004551.t005){#pone-0004551-t005-5}

                                                   1995            1996        1997   1998       1999             2000              2001              2002              2003             2004            2005            2006             2007              Total
  ------------------------------------------- --------------- --------------- ------ ------ --------------- ----------------- ----------------- ----------------- ----------------- --------------- --------------- --------------- ----------------- -----------------
  Total patients treated with MAS~3~                482             276         29    170         280              98                406               212               252              338             400             183              138              3264
  Inconclusive (N)                                   0               0          0      0           1                1                 4                 0                 0                2               4               3                0                15
  Missing (N)                                       11               3          0      0           0                2                 3                 0                 1                9               2               0                2                33
  Novel infections (N)                              11               5          0      1           7               13                29                12                13               23              30              25                8                177
  Days to novel infection median, \[range\]    35 \[21--64\]   42 \[35--63\]    \-     37    36 \[28--42\]   36.5 \[20--49\]   34.5 \[14--63\]    42 \[21--63\]    43.5 \[14--63\]   34 \[13--61\]   43 \[14--70\]   33 \[21--63\]   31.5 \[14--50\]   34.0 \[13--45\]
  Recrudescent infections (N)                        8               5          0      0           1                7                14                 8                 9               20              25               7                4                108
  Days to recrudescence median, \[range\]      21 \[14--41\]   21 \[16--36\]    \-     \-         21          23 \[15--33\]     21 \[14--42\]    23.5 \[21--42\]    21 \[7--28\]     21 \[15--42\]   23 \[14--42\]   28 \[21--42\]    28 \[23--34\]     21 \[7--42\]

Parasitological efficacy (non PCR-adjusted) increased significantly over time as the risk of *P. falciparum* parasites recurrence within 42 days of follow-up, after controlling for age, sex, mixed parasite infections, gametocyte and parasitaemia on admission, decreased (AHR = 0.88; 95% CI, 0.86--0.91, *p* = 0.001).

A small but statistically significant decline in PCR-adjusted parasitological efficacy (assessed at day-42) was observed over the study period (HR = 1.13; 95% CI, 1.07--1.19, *p*\<0.001). However the efficacy of MAS~3~ in 2007 remained above 95%: 96.5% (95% CI, 91.0--98.7), ([**Figure 3**](#pone-0004551-g003){ref-type="fig"}). The temporal trend of a slight decline in MAS~3~ efficacy remained after controlling for age, sex, baseline parasitaemia and gametocytaemia, mixed infections and the patients\' enrolment location (AHR = 1.11; 95% CI, 1.02--1.21, *p* = 0.020).

![PCR-adjusted parasitological efficacy (95% CI) at Day-42 following MAS~3~ treatment.\
Parasitological efficacy (PCR-adjusted) of the mefloquine-artesunate 3-day combination therapy was evaluated at Day-42 of follow-up between 1995 and 2007. Efficacy is given as a percentage (95% CI).](pone.0004551.g003){#pone-0004551-g003}

In vitro drug sensitivity {#s3d}
-------------------------

In total, 1,581 *P. falciparum* isolates were assayed for in vitro drug susceptibility during the study period; artesunate IC~50~ could be determined satisfactorily in 1,179 (75%) isolates and mefloquine IC~50~ in 1,195 (76%). Between 1995 and 2001 there was a significant decrease in the IC~50~s of both artesunate (13% per year, *p*\<0.001) and mefloquine (9.1% per year, *p*\<0.001). From 2002 this trend reversed for artesunate with IC~50~s increasing 41% per year (*p*\<0.001) until 2006, although decreasing in 2007 ([**Figure 4a**](#pone-0004551-g004){ref-type="fig"}). Mefloquine IC~50~s also rose between 2001 and 2004, but fell again in 2006--7 ([**Figure 4b**](#pone-0004551-g004){ref-type="fig"}). Between 1995 and 2007, the geometric mean mefloquine IC~50~ fell from 95.5 nM/l (95% CI, 70.4--129.7) to 37.1 nM/l (95% CI, 26.5--52.3, *p*\<0.001), and the IC~50~ of artesunate from 6.47 nM/l (95% CI, 5.34--7.86) to 4.19 nM/l (95% CI, 3.20--5.46, *p* = 0.009).

![Drug sensitivity of *P. falciparum* isolates for artesunate (Figure 4a) and mefloquine (Figure 4b).\
Isolates from primary infections were collected at SMRU clinics between 1995 and 2007 and assayed for sensitivity to artesunate and mefloquine, IC~50~ geometric means are given as nM/l with \[95% CI\].](pone.0004551.g004){#pone-0004551-g004}

*Pfmdr1* copy number {#s3e}
--------------------

A total of 531 isolates were selected randomly for genetic analysis with *pfmdr1* copy number successfully determined in 84% (444/531) of these isolates. The proportion of infections with two or more *pfmdr1* copy number rose from 30% (12/40) in 1996 to 53% (24/45) in 2006 (*p* = 0.012, test for trend), ([**Table 6**](#pone-0004551-t006){ref-type="table"} **and** [**Figure 5**](#pone-0004551-g005){ref-type="fig"}).

![Proportion of primary infections with increased *Pfmdr1* (≥2) copy number.\
Isolates from primary infections were used for genetic analysis between 1996 and 2006. Increase in isolates with 2 or more copy number is given in percentage of the total.](pone.0004551.g005){#pone-0004551-g005}

10.1371/journal.pone.0004551.t006

###### *Pfmdr1* copy number in parasite isolates collected in patients with primary uncomplicated *P. falciparum* infection.

![](pone.0004551.t006){#pone-0004551-t006-6}

                                                           1996       1997       1999       2001       2002       2003       2004       2005       2006
  ----------------------------------------------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  Total isolates collected                                  50         53         60         68         76         46         61         67         50
  Isolates with determination of *pfmdr1* copy number       40         49         47         57         70         36         45         55         45
  *Pfmdr1* copy number:                                                                                                                         
  \- 1                                                   28 (70%)   29 (59%)   27 (58%)   37 (65%)   52 (74%)   24 (66%)   18 (40%)   27 (49%)   21 (47%)
  \- 2                                                   8 (20%)    7 (14%)    11 (23%)   10 (18%)   12 (17%)   6 (17%)    13 (29%)   16 (29%)   11 (24%)
  \- ≥3                                                  4 (10%)    13 (27%)   9 (19%)    10 (17%)    6 (9%)    6 (17%)    14 (31%)   12 (22%)   13 (29%)

Among 408 patients treated with MAS~3~ regimen for whom in vivo and molecular data were available, 183 (45%) were infected with parasites with increased *pfmdr1* copy number. Infections with increased *pfmdr1* copy number were at greater risk of recrudescence by day-42 compared to single copy number infections (AHR = 10.0; 95% CI, 3.0--33.3, *p*\<0.001). There was no difference in the proportion of patients parasitaemic on day-2 in those with single (25%, 46/188) or increased *pfmdr1* copy number (22%, 34/155, *p* = 0.61), even after controlling for baseline parasitaemia.

In the 394 isolates with in vitro and molecular data, amplification of *pfmdr1* was associated with a 2.9 fold increase in mefloquine IC~50~ (geometric mean = 42.2 nM/l; 95% CI, 37.9--46.8 to 120.8 nM/l; 95% CI, 107.0--136.2, *p*\<0.001) and a 1.7 fold increase in artesunate IC~50~ (1.99 nM/l; 95% CI, 1.81--2.19 to 3.33 nM/l; 95% CI, 2.94--3.80, *p*\<0.001). The rise in IC~50~ associated with increased *pfmdr1* copy number was greater during the period 1996--2001 compared to thereafter for both artesunate (Pre: 2.1 *vs.* Post: 1.4 fold, *p* = 0.007) and mefloquine (Pre: 3.5 *vs.* Post: 2.6 fold; *p* = 0.076). In contrast there was no change in the risk of treatment failure associated with increased copy number over the study period.

Discussion {#s4}
==========

The rapid development of mefloquine resistance in Tak province on the Thai-Myanmar border in the early 1990s led to the introduction of the three day combination of artesunate and mefloquine (MAS~3~) as first line treatment for uncomplicated *P. falciparum* malaria in 1994 in the camps for displaced persons. Despite the prevailing high levels of mefloquine resistance, cure rates increased to more than 90% and MAS~3~ had a spectacular impact on the incidence of *P. falciparum* malaria cases in the camps [@pone.0004551-Nosten2]. In vitro susceptibility of *P. falciparum* isolates to mefloquine improved significantly until 1999, attributed to the eradication of the more mefloquine resistant "strains" and the return of more mefloquine-sensitive "wild-type" parasites [@pone.0004551-Brockman2]. This was explained by the considerably reduced transmission advantage of mefloquine-resistant parasites when treated by MAS~3~, which are less fit than their mefloquine-sensitive counterparts [@pone.0004551-Preechapornkul1], and consequent repopulation by "wild type" parasites from Myanmar (which there is little or no drug pressure) [@pone.0004551-White3].

Over the subsequent 13 years of continuous MAS~3~ deployment the cure rates assessed at day-42 remain well above 90%. However despite this unprecedented level of sustained efficacy over the 13 year period and a significant decline in the prevalence of falciparum malaria on the Thai side of the border, there are some worrying trends. The in vitro susceptibility of *P. falciparum* isolates to artesunate has now returned to the levels observed in 1995, although the magnitude of this change is small (+/−4 nM) and within the accepted drug sensitivity levels. Mefloquine susceptibility has fluctuated widely, and its association with the *pfmdr1* copy number seems to have changed over the years. These changes in antimalarial activity in vitro have not been associated with a sharp reduction in cure rates, as happened when mefloquine was used as monotherapy [@pone.0004551-Nosten1], [@pone.0004551-Nosten2]. The changes in artesunate susceptibility could be related to the increases in *pfmdr1* copy number [@pone.0004551-Price2] although the patterns are dissimilar, and not well correlated with changes in mefloquine susceptibility. Over the last 4 years, there has been no further increase in the proportion of isolates with increased *pfmdr1* copy number, and yet there are indications that artemisinin efficacy has declined as evidenced by an increase in the parasite clearance time. The decrease in in vitro susceptibility to artesunate after 2002 could not be explained by mechanisms associated with mefloquine resistance (predominantly *pfmdr1* amplification). The correlation between artesunate and mefloquine IC~50~s evident before 2002 was no longer evident afterwards. This suggests the emergence of a new factor affecting artesunate susceptibility, which could include either novel mutations within the *pfmdr1* gene, increased gene expression or alternate genetic events.

The changes in the early in vivo parasitological responses to MAS~3~ are more concerning. Rapid parasite clearance is the pharmacodynamic hallmark of artemisinin and its derivatives. This is associated with reduced gametocyte carriage compared with other antimalarial drugs. There has been a small but significant slowing of parasite clearance, reflected by the increasing proportion of patients with parasitaemia persisting on the second and subsequent days following the start of treatment. Up until 2001 less than 7% of patients were parasitaemic on the second day of follow-up; however this figure has more than doubled in recent years. The delay in parasite clearance has been associated with a small increase in treatment failure rates, presumably reflecting a slight reduction in initial parasite reduction ratios, which results in a greater number of parasites for mefloquine to remove in the third and subsequent post treatment replication cycles [@pone.0004551-White1]. Slowing of parasite clearance was associated with increased gametocyte carriage, and therefore presumably increased transmissibility of the more drug tolerant phenotype. This is an important public health point as the marked effect of artemisinin derivatives in reducing gametocyte carriage is an important contributor to their beneficial effects in malaria transmission control. Increased rates of gametocyte carriage were a harbinger of sulfadoxine-pyrimethamine resistance in Southern Africa, before any discernable effect on cure rates [@pone.0004551-Barnes1]. The dissociation between in vitro and in vivo observations suggests that the conventional in vitro approach to susceptibility testing may not be appropriate for evaluating artesunate tolerance. These are very early signs detectable only in this site, with the largest and most detailed longitudinal experience of antimalarial drug responses in the world. Several different factors affect cure rates. Young age of the patients, pure *P. falciparum* infections rather than infections mixed with *P. vivax* on admission, a parasitaemia over 40,000 parasites per µl on admission and site have been found to be independent risk factors for treatment failure following MAS~3~ [@pone.0004551-Price1]. However the temporal trends remain significant even after controlling for all these factors. The efficacy of the 3-day MAS regimen falls when the level of mefloquine resistance increases such that drug levels remaining after artesunate has been eliminated are not sufficient to eliminate completely the residual parasites. Mefloquine resistance arises readily as a result of gene amplification [@pone.0004551-Price2]. Drug pressure, and therefore the risk of selecting mefloquine resistant parasites results from increasing drug use, inadequate regimens, and from unprotected monotherapy [@pone.0004551-White4]. Mefloquine has been used scantily within Myanmar. The 2-day regimen that was used by the Thai national programme was instituted in the early years of the combination therapy, based on non-PCR adjusted cure rates at 28 days of follow-up [@pone.0004551-Thimasarn1] and on the assumption that adherence to a two day regimen would be better than that with a three day regimen [@pone.0004551-Wongsrichanalai1]. However with a two-day regimen, blood levels of artesunate cover one parasite asexual cycle only, so residual numbers of parasites left for the mefloquine component to remove are up to four orders of magnitude higher than with the three day regimen. This would be expected to increase the selection pressure for the emergence and spread of mefloquine resistant strains [@pone.0004551-Nosten3]. Drug pressure may have been further aggravated by the lower mefloquine dosage (15 mg/kg) used in monotherapy in 62 out of the 76 Thai provinces until recently [@pone.0004551-Vijaykadga1]. However the inconsistent trend in the in vitro susceptibility assessments of mefloquine and the lack of any shortening in the interval to recrudescence argues against a major decline in mefloquine susceptibility.

Despite some worrying signs, which could only have been detected by these very large prospective studies, the 3-day mefloquine-artesunate combination is still more than 95% effective in Tak province, 13 years after its introduction in the camps for displaced persons. Considering that resistance to mefloquine monotherapy had reached very high levels before this combination was deployed, and that surrounding areas deployed different dose regimens, its longevity is remarkable. Our data suggest that changes have occurred in the prevalent *P. falciparum* population resulting in small but significant increases in parasite tolerance to the artesunate component of MAS~3~. These are considerably less in magnitude than those reported recently from Western Cambodia [@pone.0004551-White5] but they may be the harbinger of much higher levels of artemisinin tolerance. Although *pfmdr1* amplification is a contributor to artemisinin susceptibility, the main cause of this reduction in artesunate susceptibility is not known. Of particular concern is the increased transmissibility of these tolerant parasites. The changes are small, but they justify a very close monitoring of the susceptibility of *P. falciparum* in this area, and in particular vigilance to detect early emergence of higher levels of artemisinin resistance. The development of resistance to artemisinin and its derivatives would be a global disaster for malaria control as current treatment regimen are dependant on this class of antimalarial drugs.
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